3D Printed Drugs Market Size By End User, By Region 2021 | Overview, Growth, Economics, Demand And Forecast Research Report To 2027
Research report presented by UnivDatos, Emphasis on Technology
(Inkjet Printing, Fused Deposition Modelling, Stereolithography, Others),
Application (Orthopaedic, Neurology, Hearing & Audibility Aid, Medical
Implants, Dental, Others), Drug Form (Tablet, Capsules, Multi Drug Implants,
Nano Particles, Solutions, Nano Suspension, Encapsulated within a Polymer,
Implant), Drugs (Spritam, Others), End-Users (Hospitals, Clinics, Research
Laboratories),and Geographical analysis (key regions and countries).
As per the research report, the global 3D Printed Drugs Market is expected to reach the market valuation of US$
2,064.8 million by 2027 expanding at a reasonable CAGR of 15.2% during the forecast
period (2021-2027) from US$ 638.6 million in 2019.
The
government's investment in 3D printing technology, venture capital for 3D
printing start-ups, and pharma companies' investment in 3D printing technology
are all driving growth in the global 3D printed drugs market. According to a
study, about 63 percent of pharmaceutical firms are considering investing in 3D
printing technology, and the number of professionals using 3D printing
technology is three times higher than it was three years before, in 2017. One
of the most important factors behind industry growth is venture capital support
for 3D printing. Furthermore, the Austrian federal government and the state of
Lower Austria jointly proposed two financing packages for 2020 that would
promote developments in new emerging technology, including 3D printing.
For complete research, request for
Sample of the report browse through – https://univdatos.com/request_form/form/353
Furthermore,
the increasing prevalence of chronic illness and the growing number of patients
around the world are driving demand for soluble medications, which is driving
demand for customizable 3D printing medication. Dysphagia affects approximately
9 million people in the United States each year, according to a survey, and is
particularly prevalent among the elderly. Dysphagia affects 50-75 percent of
stroke patients and 60-70 percent of head and neck cancer patients who receive
radiation therapy. Because of the growing demand worldwide, governments around
the world are spending more in healthcare and putting a greater focus on 3D
printing technologies for faster manufacturing. According to the OCED, the US
government spent USD 8,032.6 per capita in 2015, which increased to USD 9,386.5
per capita in 2019. In the United Kingdom, the government spent USD 3,043.6 per
capita in 2015, which increased to USD 3619.5 per capita in 2019.
In
addition, as the government places a greater focus on personalised medications
and as end-users become more conscious of the advantages of 3D printed
products, such as high doses in a single pill, swallowability, and various
forms of drugs, the market for 3D printed medicines is growing.
For a detailed analysis of the applications in the 3D Printed
Drugs Market browse through – https://univdatos.com/report/global-3d-printed-drugs-market-current-analysis-and-forecast-2020-2027
COVID-19 Impact -
As a
result of the COVID 19 pandemic, the market for drugs, medical instruments, and
accessories has increased, resulting in an increase in the use of 3D printing.
Because of its robotic processing capability, 3D printing is a quicker manufacturing
process. Several printers have been introduced by firms in the additive
manufacturing industry to further improve the manufacture of drugs and other
necessary goods. During the COVID pandemic, HP provided researchers with the
"D300e Bioprinter" to help in the production of a vaccine and
medicines to combat COVID-19 in the United States and Europe. Furthermore, the
opioid crisis during the COVID pandemic has piqued pharma companies' interest
in delivering drugs quickly. According to the National Institute of Health of
the United States, medication shortages in 2020 will be 87 percent of those
registered in 2019 in half the period. When contemplating the impact of the
second wave of COVID-19 cases, it's possible the drug shortages will worsen.
Insights Presented in the Report
“Amongst applications, neurology is expected to dominate the market
during the analyzed period”
The
market is divided into Orthopedic, Neurology, Hearing & Audibility Aid,
Medical Implants, Dental, among Others based on the applications. In 2019, the
neurology division captured the majority of the market share, accounting for
35.1 percent of total sales. The rising prevalence of neurological disorders is
causing this section to rise in size. According to a
survey, neurological disabilities are the leading cause of disability
worldwide, with about 1 billion people afflicted by a kind of neurological
illness. Furthermore, during the forecast period of 2021-2027, the orthopaedic
segment is projected to rise at a CAGR of more than 15.9%.
“Amongst technology, inkjet
printing segment holds the major share”
The market is divided into inkjet
printing, fused deposition modelling, stereolithography, and other product
types. Because
of advantages such as low cost, programmability, high resolution, high
throughput, high speed, and biocompatibility of these printers, as well as the
introduction of new products by key players in the industry, the inkjet
printing segment dominated the market with a share of 42.2 percent in 2019 and is
expected to continue its dominance throughout the forecast period.
“Amongst drug form, the tablet is expected to dominate the market during
the analyzed period”
The
industry is divided into pill, capsules, multidrug implants, nanoparticles,
solutions, nanosuspension, encapsulated inside a polymer, among others,
depending on the medication type. In 2019, the tablet division captured the
majority of the market share, accounting for 29.8% of total sales. Tablets have
advantages such as a longer shelf life and a range of shapes. In addition,
compared to a capsule, it can hold a larger dose of an active ingredient.
Furthermore, during the forecast period of 2021-2027, the capsule segment is
projected to expand at a CAGR of more than 15.8%.
“North America represents one of the largest markets of the 3D Printed
Drugs market”
A
systematic research was performed for various regions around the globe,
including North America (the United States, Canada, and the Rest of North
America), Europe (Germany, France, Italy, United Kingdom, Spain, and Rest of
Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and the
Rest of APAC), and the Rest of the World, to get a greater understanding of the
consumer conditions of 3D Printed Drugs. Because of rising healthcare IT spending in
countries such as the United States and Canada, North America led the industry
in 2019, generating sales of US$ 306.8 million. Furthermore, the region's
dominance across the globe is due to the involvement of well-established
players in additive manufacturing.
Customization Options:
The 3D Printed Drugs Market can further be customized as
per the requirement or any other market segment. Besides this, UMI understands
that you may have your own business needs, hence feel free to connect with us
to get a report that completely suits your requirements.
Table of Contents
1 Market
Introduction
2 Research
Methodology or Assumption
3 Industry
Performance
4 Executive
Summary
5 Case
Studies
6 COVID-19
Impact
7 Market
Insights by Technology
8 Market
Insights by Application
9 Market
Insights by Drug Form
10 Market
Insights by Drug
11 Market
Insights by End-User
12 Market
Insights by Region
13 3d Printed
Drugs Market Dynamics
14 Legal &
Regulatory Framework
15 Demand and
Supply Side Analysis
16 Value Chain
Analysis
17 3d Printed
Drugs Market Hotspot & Opportunities
18 3d Printed
Drugs Market Trends & Insights
19 Competitive
Scenario
20 Company
Profiled - Aprecia Pharmaceuticals, LLC., GlaxoSmithKline plc,
AstraZeneca, FabRx Ltd., Hewlett Packard Caribe, Merck KGaA, Cycle
Pharmaceuticals, Tvasta
21 Disclaimer
About Us:
UnivDatos
Market Insights (UMI), is a passionate market research firm and a subsidiary of
Universal Data Solutions. Rigorous secondary and primary research on the market
is our USP, hence information presented in our reports is based on facts and
realistic assumptions. We have worked with 200+ global clients, including some
of the fortune 500 companies. Our clientele praises us for quality of insights,
In-depth analysis, custom research abilities and detailed market segmentation.
Labels: 3d Printed Drugs Market
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home